The Program — What Happens Next — The Evidence — About Dr. Hare — Why Physician-Led The Limitless Protocol Why Limitless Services — Hormone Therapy — Low Testosterone — Testosterone Pellets — Women's Hormone Therapy — Medical Weight Loss — Tirzepatide — Semaglutide — Moving Your GLP-1 Care — Peptide Therapy — Peptide Menu — Cognitive Peptides — IV Therapy & NAD+ — NAD+ IV near Chattanooga — Cost & Payment Research — Retatrutide Update — Peptide Reclassification Update — The Case for Creatine Locations Assessment Request a consultation
FDA status, October 2026: not approved. Eli Lilly plans to file with the FDA in the first quarter of 2027.
Weight Loss · FDA Status · Updated October 2026

Retatrutide in 2026 — its FDA status and what the Phase 3 data says.

As of October 2026, retatrutide is investigational and not FDA-approved. The only legitimate routes to it are a clinical trial or Lilly's expanded access program. Limitless prescribes tirzepatide (Zepbound) and semaglutide (Wegovy) for weight loss when either fits your labs and history.

Eli Lilly's triple-agonist obesity drug — GLP-1, GIP, and glucagon receptors all activated by one molecule — is now the most-watched compound in metabolic medicine. Here is what the TRIUMPH program has shown, when it might reach the market, and what it changes about how we approach weight loss.

The Headline

The biggest weight-loss number in a Phase 3 obesity trial when it was published.

In December 2025, Eli Lilly reported topline results from TRIUMPH-4, the first Phase 3 readout for retatrutide (LY3437943). Patients on the 12 mg once-weekly dose lost a mean of 28.7% of their body weight over 68 weeks — an average of 71.2 pounds. The 9 mg arm produced 26.4% mean loss. Placebo: 2.1%.

For perspective: tirzepatide (Mounjaro/Zepbound) tops out around 22.5% in its longest Phase 3 trials. Semaglutide (Wegovy) tops out around 14.9%. Retatrutide produced more weight loss in this single trial than any prior Phase 3 obesity compound has ever produced — and the trial population was patients with obesity and knee osteoarthritis, a group that is typically harder to budge because they cannot exercise as freely.

28.7%
Mean weight loss
12 mg dose, 68 weeks, TRIUMPH-4 (vs. 2.1% placebo)
71.2 lbs
Absolute weight loss
Average pounds lost on the 12 mg arm
75.8%
Knee OA pain reduction
WOMAC pain score reduction. 1 in 8 patients was pain-free at end of trial.
"If TRIUMPH-1 and TRIUMPH-2 reproduce TRIUMPH-4's numbers in 2026, retatrutide will redefine the upper limit of pharmacologic weight loss. The question stops being 'how much weight can a drug move' and starts being 'how do we use this responsibly.'"
The Mechanism

Why a triple agonist moves more weight than a single or dual.

Retatrutide is the first triple agonist to reach Phase 3. Each receptor it hits contributes a different effect:

The clinical translation: glucagon agonism turns up the metabolic furnace while GLP-1 turns down appetite. Most prior weight-loss drugs only addressed input. Retatrutide addresses both input and output simultaneously.

Where Retatrutide Sits

How it stacks against the current standard of care.

Three drugs dominate the conversation in 2026: semaglutide (Wegovy), tirzepatide (Zepbound), and retatrutide (investigational). Here is the plain comparison, anchored to the published Phase 3 data.

Semaglutide (Wegovy) Tirzepatide (Zepbound) Retatrutide
Mechanism Single agonist (GLP-1) Dual agonist (GLP-1 + GIP) Triple agonist (GLP-1 + GIP + glucagon)
Mean weight loss (Phase 3) ~14.9% over 68 weeks ~22.5% over 72 weeks ~28.7% over 68 weeks (TRIUMPH-4)
Dosing Weekly injection Weekly injection Weekly injection (investigational)
FDA status (October 2026) Approved (obesity, T2D, MACE) Approved (obesity, T2D, OSA) Investigational — filing planned for Q1 2027
Approval timeline Available now Available now Anticipated late 2027 / early 2028

Phase 3 weight-loss figures are mean values from the largest published trials at maximum tolerated dose. Individual response varies widely. SURMOUNT-5 is the only direct head-to-head comparison of tirzepatide and semaglutide; retatrutide head-to-head data versus tirzepatide is not yet available.

Safety Signal Watch

What the TRIUMPH-4 data shows about tolerability.

The efficacy headline is enormous, but Phase 3 readouts are also where safety signals emerge. Three things are worth tracking as the rest of the TRIUMPH program reports out in 2026:

Eli Lilly has explicitly designed the TRIUMPH program to interrogate a maintenance dose (4 mg) precisely because the 12 mg dose may produce more weight loss than is sustainable or desirable for a given patient. This is a maturation of how the field thinks about these drugs — less "maximum dose forever" and more "induction phase, then maintenance."

The Timeline

When patients can realistically expect retatrutide.

01

2026 — Trial readouts

TRIUMPH-1 reported in May 2026, and TRIUMPH-2 and TRIUMPH-3 in July. Lilly says its clinical data package for obesity, knee osteoarthritis pain, and obstructive sleep apnea is now complete.

02

Q1 2027 — FDA filing

Eli Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027, while it completes its manufacturing data. That is later than the late-2026 filing once expected.

03

Late 2027 – 2028 — FDA decision

A standard FDA review takes about a year from filing, and a priority review about eight months. Either way, a decision would come in late 2027 or early 2028.

04

2027–2028 — Launch

Anticipated commercial launch with branded product. Compounded retatrutide is not currently available through licensed pharmacies; we do not source from gray markets.

Critically: retatrutide is investigational as of October 2026 and is not legally compoundable through 503A or 503B pharmacies because it is not on the FDA's compounding-eligibility list. We do not prescribe research-grade or gray-market product. Patients who want triple-agonist effect now are working with us on tirzepatide-based protocols paired with peptide and lifestyle adjuncts that approximate some of the metabolic benefit.

What This Changes

The strategic implications for weight-loss patients in 2026.

Frequently Asked

Retatrutide questions, answered.

Is retatrutide FDA-approved?
No. As of October 2026, Eli Lilly has not yet filed it. The company says its clinical data package is complete and that it plans to submit a Biologics License Application to the FDA in the first quarter of 2027 (Lilly, August 5, 2026). A standard review takes about a year from filing, so a decision would come in late 2027 or early 2028.
Can I get retatrutide prescribed today?
No. As of October 2026, retatrutide is investigational and not FDA-approved. It cannot be legally compounded. There are two legitimate routes: a registered clinical trial, or Lilly's narrow pre-approval expanded access program. A treating physician requests it for adults who have a BMI of 35 or more despite the highest available dose of a weight-management drug, who have two or more serious obesity-related complications, and who have no way to join a trial. Any source selling retatrutide outside those routes is selling research-grade product without sterility, identity, or potency documentation. We do not prescribe from those sources.
How can I participate in a retatrutide clinical trial?
Eli Lilly's TRIUMPH program enrolls through specific clinical trial sites listed on ClinicalTrials.gov. We can help you identify the closest enrolling site if you are interested in participating, but Limitless does not run trial sites directly.
Will retatrutide replace tirzepatide?
Probably not — it will likely supplement it. The pricing, payer access, and patient tolerability of a much higher-potency drug will create a tier system: tirzepatide for moderate weight loss goals, retatrutide for higher BMI or tirzepatide non-responders. This is similar to how tirzepatide did not replace semaglutide.
Is retatrutide a "miracle drug"?
No drug is. The 28.7% weight loss is real, but so are GI side effects, the cost (anticipated to be substantial), the lifelong-therapy expectation, and the muscle-preservation challenge. Retatrutide will be a powerful tool. It will not change the fundamentals of metabolic health — sleep, training, nutrition, hormone balance.
What is the difference between TRIUMPH-1, -2, -3, and -4?
TRIUMPH-1: obesity, no diabetes (largest registration trial). TRIUMPH-2: obesity or overweight with type 2 diabetes. TRIUMPH-3: obesity with established cardiovascular disease (a weight-loss trial). The separate cardiovascular and kidney outcomes trial runs into 2029. TRIUMPH-4: obesity with knee osteoarthritis (the December 2025 readout). TRIUMPH-5 compares retatrutide directly with tirzepatide, and the later TRIUMPH trials study weight maintenance, people with chronic low back pain, and other populations.
How Limitless Approaches This

Our weight-loss program, in plain language.

Limitless is a physician-led practice — Joshua Hare, DO supervises every protocol. For weight loss specifically, our framework has four parts:

When retatrutide launches, it will join the formulary. Until then, we use what is available — well.

Read Next

Continue the weight-loss series.

Editorial note. This article summarizes publicly available Phase 3 trial data on retatrutide (LY3437943). The retatrutide trial figures are from TRIUMPH-4 (December 2025), and the FDA status on this page was updated in October 2026. Retatrutide is an investigational drug and is not FDA-approved. Nothing here is medical advice or a prescription. Trial outcome figures are mean values; individual response varies. Clinical decisions about weight-loss therapy require a physician evaluation, lab work, and ongoing monitoring. If you are considering GLP-1 or GLP-1/GIP therapy, schedule a consultation.

Don't wait for the next drug to start.

The current generation of approved therapies is already the most effective weight-loss medication ever made available. We design protocols that work now and that you can transition off of — or onto retatrutide — when the time is right.

Request a consultation

Take the Assessment · 90 sec